SK9342002A3 - Combination chemotherapy - Google Patents

Combination chemotherapy Download PDF

Info

Publication number: SK9342002A3
Authority: SK; Slovakia
Prior art keywords: dose; docetaxel; cancer; combination; treatment
Prior art date: 2001-07-02

Application number

SK934-2002A

Other languages

English (en)

Slovak (sk)

Inventor

William Richard Grove

Ronald Lynn Merriman

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-02

Filing date

2002-06-26

Publication date

2003-07-01

2002-06-26 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2003-07-01 Publication of SK9342002A3 publication Critical patent/SK9342002A3/sk

Links

238000009096 combination chemotherapy Methods 0.000 title description 2
VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 claims abstract description 84
206010028980 Neoplasm Diseases 0.000 claims abstract description 58
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims abstract description 56
229960003668 docetaxel Drugs 0.000 claims abstract description 55
201000011510 cancer Diseases 0.000 claims abstract description 13
238000011282 treatment Methods 0.000 claims description 49
238000000034 method Methods 0.000 claims description 15
230000000259 anti-tumor effect Effects 0.000 claims description 13
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 9
206010006187 Breast cancer Diseases 0.000 claims description 7
208000026310 Breast neoplasm Diseases 0.000 claims description 7
241001465754 Metazoa Species 0.000 claims description 7
239000002775 capsule Substances 0.000 claims description 6
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
238000001802 infusion Methods 0.000 claims description 5
206010060862 Prostate cancer Diseases 0.000 claims description 4
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
238000001990 intravenous administration Methods 0.000 claims description 4
229950010692 docetaxel trihydrate Drugs 0.000 claims description 2
XCDIRYDKECHIPE-QHEQPUDQSA-N docetaxel trihydrate Chemical compound O.O.O.O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 XCDIRYDKECHIPE-QHEQPUDQSA-N 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
208000009956 adenocarcinoma Diseases 0.000 claims 1
229940046044 combinations of antineoplastic agent Drugs 0.000 claims 1
230000001394 metastastic effect Effects 0.000 claims 1
206010061289 metastatic neoplasm Diseases 0.000 claims 1
210000000496 pancreas Anatomy 0.000 claims 1
239000008174 sterile solution Substances 0.000 claims 1
230000002195 synergetic effect Effects 0.000 abstract description 4
231100000682 maximum tolerated dose Toxicity 0.000 description 24
230000000694 effects Effects 0.000 description 23
239000003814 drug Substances 0.000 description 15
239000000203 mixture Substances 0.000 description 14
230000004044 response Effects 0.000 description 14
229940079593 drug Drugs 0.000 description 13
238000002360 preparation method Methods 0.000 description 10
231100000331 toxic Toxicity 0.000 description 10
230000002588 toxic effect Effects 0.000 description 10
230000003111 delayed effect Effects 0.000 description 9
230000002411 adverse Effects 0.000 description 8
230000008485 antagonism Effects 0.000 description 8
230000004614 tumor growth Effects 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
210000004881 tumor cell Anatomy 0.000 description 7
206010047700 Vomiting Diseases 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
238000009472 formulation Methods 0.000 description 6
230000036961 partial effect Effects 0.000 description 6
208000037844 advanced solid tumor Diseases 0.000 description 5
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 5
229960005277 gemcitabine Drugs 0.000 description 5
238000011084 recovery Methods 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
102000029749 Microtubule Human genes 0.000 description 4
108091022875 Microtubule Proteins 0.000 description 4
230000009471 action Effects 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000008030 elimination Effects 0.000 description 4
238000003379 elimination reaction Methods 0.000 description 4
230000002489 hematologic effect Effects 0.000 description 4
210000004688 microtubule Anatomy 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
230000008673 vomiting Effects 0.000 description 4
206010009944 Colon cancer Diseases 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
206010028813 Nausea Diseases 0.000 description 3
206010033128 Ovarian cancer Diseases 0.000 description 3
206010061535 Ovarian neoplasm Diseases 0.000 description 3
206010061902 Pancreatic neoplasm Diseases 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
201000010536 head and neck cancer Diseases 0.000 description 3
208000014829 head and neck neoplasm Diseases 0.000 description 3
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
230000008693 nausea Effects 0.000 description 3
201000002528 pancreatic cancer Diseases 0.000 description 3
208000008443 pancreatic carcinoma Diseases 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
206010043554 thrombocytopenia Diseases 0.000 description 3
206010065553 Bone marrow failure Diseases 0.000 description 2
208000005156 Dehydration Diseases 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000004820 blood count Methods 0.000 description 2
230000000973 chemotherapeutic effect Effects 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
230000000174 oncolytic effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000011885 synergistic combination Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
208000000187 Abnormal Reflex Diseases 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
241000132092 Aster Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000012766 Growth delay Diseases 0.000 description 1
206010066476 Haematological malignancy Diseases 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000013038 Hypocalcemia Diseases 0.000 description 1
206010022095 Injection Site reaction Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010059282 Metastases to central nervous system Diseases 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010033647 Pancreatitis acute Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
206010045170 Tumour lysis syndrome Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
201000003229 acute pancreatitis Diseases 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000001946 anti-microtubular Effects 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
208000006218 bradycardia Diseases 0.000 description 1
230000036471 bradycardia Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
201000006662 cervical adenocarcinoma Diseases 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000371 dose-limiting toxicity Toxicity 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000035859 hyperreflexia Effects 0.000 description 1
206010020745 hyperreflexia Diseases 0.000 description 1
230000000705 hypocalcaemia Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000016507 interphase Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
230000037321 sleepiness Effects 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
231100000338 sulforhodamine B assay Toxicity 0.000 description 1
238000003210 sulforhodamine B staining Methods 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
208000010380 tumor lysis syndrome Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Seasonings (AREA)
Medicinal Preparation (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Insulated Conductors (AREA)

SK934-2002A 2001-07-02 2002-06-26 Combination chemotherapy SK9342002A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US30241501P	2001-07-02	2001-07-02

Publications (1)

Publication Number	Publication Date
SK9342002A3 true SK9342002A3 (en)	2003-07-01

Family

ID=23167645

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK934-2002A SK9342002A3 (en)	2001-07-02	2002-06-26	Combination chemotherapy

Country Status (20)

Country	Link
US (1)	US20030083366A1 (es)
EP (1)	EP1273296B1 (es)
JP (1)	JP2003055208A (es)
KR (1)	KR20030015829A (es)
CN (1)	CN1394601A (es)
AT (1)	ATE254915T1 (es)
AU (1)	AU5063302A (es)
CA (1)	CA2391753A1 (es)
CZ (1)	CZ20022216A3 (es)
DE (1)	DE60200101T2 (es)
DK (1)	DK1273296T3 (es)
ES (1)	ES2208626T3 (es)
HK (1)	HK1049794A1 (es)
HU (1)	HUP0202120A3 (es)
IL (1)	IL150396A0 (es)
PL (1)	PL354825A1 (es)
PT (1)	PT1273296E (es)
SK (1)	SK9342002A3 (es)
TR (1)	TR200302193T4 (es)
ZA (1)	ZA200205216B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20050206A1 (es) *	2003-05-26	2005-03-26	Schering Ag	Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
US9839667B2 (en)	2005-10-14	2017-12-12	Allergan, Inc.	Prevention and treatment of ocular side effects with a cyclosporin
EP2404596A1 (en) *	2006-03-23	2012-01-11	TMRC Co., Ltd.	Kit for Cancer Treatment and Pharmaceutical Composition for Cancer Treatment
AU2008272818A1 (en) *	2007-07-02	2009-01-08	Yu, Ming Dr	Methods, composition, targets for combinational cancer treatments
WO2012003413A1 (en) *	2010-06-30	2012-01-05	The Broad Institute, Inc.	Novel solid forms of tacedinaline
US8691875B2 (en)	2011-07-01	2014-04-08	Broad Institute, Inc.	Solid forms of tacedinaline

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ219974A (en) *	1986-04-22	1989-08-29	Goedecke Ag	N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU6878198A (en) *	1997-04-24	1998-11-13	Warner-Lambert Company	Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US6469058B1 (en) *	1998-09-25	2002-10-22	Warner-Lambert Company	Chemotherapy of cancer with actyldinaline in combination with gemcitabine capecitabine or cisplatin
YU45401A (sh) *	1998-12-22	2004-07-15	Warner-Lambert Company	Antikancerogena kombinacija
GB9904386D0 (en) *	1999-02-25	1999-04-21	Pharmacia & Upjohn Spa	Antitumour synergistic composition
HUP0203153A3 (en) *	1999-11-10	2005-01-28	Warner Lambert Co	Combination chemotherapy

2002
- 2002-06-24 CZ CZ20022216A patent/CZ20022216A3/cs unknown
- 2002-06-25 IL IL15039602A patent/IL150396A0/xx unknown
- 2002-06-26 ZA ZA200205216A patent/ZA200205216B/xx unknown
- 2002-06-26 AU AU50633/02A patent/AU5063302A/en not_active Abandoned
- 2002-06-26 SK SK934-2002A patent/SK9342002A3/sk not_active Application Discontinuation
- 2002-06-26 CA CA002391753A patent/CA2391753A1/en not_active Abandoned
- 2002-06-28 HU HU0202120A patent/HUP0202120A3/hu unknown
- 2002-07-01 DK DK02254337T patent/DK1273296T3/da active
- 2002-07-01 JP JP2002192378A patent/JP2003055208A/ja active Pending
- 2002-07-01 DE DE60200101T patent/DE60200101T2/de not_active Expired - Fee Related
- 2002-07-01 ES ES02254337T patent/ES2208626T3/es not_active Expired - Lifetime
- 2002-07-01 PT PT02254337T patent/PT1273296E/pt unknown
- 2002-07-01 TR TR2003/02193T patent/TR200302193T4/xx unknown
- 2002-07-01 AT AT02254337T patent/ATE254915T1/de not_active IP Right Cessation
- 2002-07-01 EP EP02254337A patent/EP1273296B1/en not_active Expired - Lifetime
- 2002-07-01 PL PL02354825A patent/PL354825A1/xx not_active Application Discontinuation
- 2002-07-02 CN CN02140132A patent/CN1394601A/zh active Pending
- 2002-07-02 US US10/187,679 patent/US20030083366A1/en not_active Abandoned
- 2002-07-02 KR KR1020020037891A patent/KR20030015829A/ko not_active Application Discontinuation
2003
- 2003-03-17 HK HK03101938.0A patent/HK1049794A1/zh unknown

Also Published As

Publication number	Publication date
US20030083366A1 (en)	2003-05-01
HU0202120D0 (es)	2002-09-28
IL150396A0 (en)	2002-12-01
DE60200101T2 (de)	2004-08-26
HUP0202120A3 (en)	2005-01-28
PT1273296E (pt)	2004-03-31
KR20030015829A (ko)	2003-02-25
HUP0202120A2 (hu)	2003-01-28
CN1394601A (zh)	2003-02-05
PL354825A1 (en)	2003-01-13
JP2003055208A (ja)	2003-02-26
TR200302193T4 (tr)	2004-02-23
ES2208626T3 (es)	2004-06-16
HK1049794A1 (zh)	2003-05-30
DK1273296T3 (da)	2004-03-01
DE60200101D1 (de)	2004-01-08
ATE254915T1 (de)	2003-12-15
AU5063302A (en)	2003-01-09
EP1273296B1 (en)	2003-11-26
CZ20022216A3 (cs)	2003-05-14
EP1273296A2 (en)	2003-01-08
EP1273296A3 (en)	2003-01-22
CA2391753A1 (en)	2003-01-02
ZA200205216B (en)	2004-02-10

Publication	Publication Date	Title
AU762079B2 (en)	2003-06-19	Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
RU2587013C2 (ru)	2016-06-10	Комбинированная химиотерапия
JP2012515184A (ja)	2012-07-05	大腸がんの治療方法
AU1583201A (en)	2001-06-06	Combination chemotherapy
WO1996019226A1 (en)	1996-06-27	Combination chemotherapy of suramin and a vinca-alkaloid or estramustine
SK9342002A3 (en)	2003-07-01	Combination chemotherapy
KR20040078123A (ko)	2004-09-08	에포틸론 및 대사길항물질을 포함하는 조합물
WO2008109349A1 (en)	2008-09-12	Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
US20030134893A1 (en)	2003-07-17	Combination chemotherapy
US20060142239A1 (en)	2006-06-29	Potassium or sodium salt of (-)-2-(4-hydroxyphenyl)ethyl!-thio-3-'4-{4-'(methzlsulfonzl)oxy !phenoxy}phenyl!propanoic acid and their use in medicine
MXPA01003074A (es)	2001-12-13	Quimioterapia para tratar el cancer con acetildinalina en combinacion con gemcitabina, capecitabina o cisplatina
CN115581703A (zh)	2023-01-10	复方吉西他滨组合物及应用

Legal Events

Date	Code	Title	Description
2010-06-07	FC9A	Refused patent application